Laurus Labs (LAURUSLABS) Share Price Falls 2.86% Today; Price Action, Valuation and Peer View

Laurus Labs Share Price fell to Rs 1,852.50 on 01 September 2026, down 2.86% for the day from the previous close of Rs 1,907.00. The move puts the Large Cap pharmaceutical company’s market capitalisation at Rs 1,04,566.62 crore and brings the stock into focus because the decline sits alongside premium valuation multiples relative to much of the Healthcare and Pharmaceuticals & Drugs universe.

The supplied data confirms the price fall but does not identify a company-specific catalyst. That is important context. A single-session decline can reflect sentiment, positioning, or valuation reassessment without proving any change in the underlying business. In Laurus Labs’ case, profitability metrics remain relatively firm, with ROE at 18.31% and ROCE at 18.20%, while valuation stays rich at a P/E of 94.24 and a P/B of 18.27.

For readers tracking Laurus Labs Share Price on Univest, the key questions are straightforward: how the stock traded during the session, how current ratios compare with industry benchmarks, and how the company stacks up against major listed peers such as Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences and Cipla.

Laurus Labs (LAURUSLABS) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,852.5
Previous Close	Rs 1,907
Today's Move	-Rs 54.50 (-2.86%)
Open	Rs 1,894.05
High	Rs 1,894.05
Low	Rs 1,851.9
Turnover	Rs 4.57 crore
Market Capitalisation	Rs 1,04,566.62 crore
Market Cap Category	Large Cap

Laurus Labs Share Price Today reflects steady weakness through the session. The stock opened at Rs 1,894.05, which also marked the day’s high, and then moved lower to Rs 1,851.90 before trading at Rs 1,852.50. Because the session high matched the opening price, the intraday pattern suggests the stock did not regain upside momentum after the market opened.

The difference between the previous close of Rs 1,907.00 and the current price amounts to a decline of Rs 54.50, or 2.86%. Trading near the day’s low often keeps short-term attention on whether selling pressure is fading or still active. Turnover stood at Rs 4.57 crore, confirming participation in the move, though turnover alone does not explain why the stock fell.

As a Large Cap name in pharmaceuticals, Laurus Labs can attract broader interest when a notable daily move appears alongside a premium earnings multiple. That is why the discussion quickly shifts from the day’s tape to the bigger question of whether fundamentals and comparative positioning justify current market expectations.

Laurus Labs (LAURUSLABS) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 1,04,566.62 crore
P/E Ratio	94.24x
P/B Ratio	18.27x
ROE	18.31%
ROCE	18.2%
EPS	Rs 20.24
Book Value Per Share	Rs 104.37
Dividend Yield	0.1%

The fundamentals present a mixed but readable picture. Laurus Labs trades at a P/E ratio of 94.24 and a P/B ratio of 18.27, both of which are elevated by ordinary sector standards. These multiples imply the market is placing a premium on the company relative to many listed pharmaceutical businesses, which can leave the stock more exposed when sentiment cools or investors reassess valuations.

Profitability, however, is not weak. ROE of 18.31% and ROCE of 18.20% show returns above broad industry central tendencies. EPS stands at Rs 20.24, book value per share is Rs 104.37, and dividend yield is 0.10%. Put together, the data points to a sizeable company with respectable returns and modest yield support, but also one that carries demanding valuation expectations.

This contrast is central to the current market reading. Laurus Labs Share Price is not being discussed only because it fell in one session; it is being discussed because a premium-rated stock has moved lower while still screening expensive on earnings and book-value multiples.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	94.24x
Benchmark Median P/E	30.92x
Benchmark Average P/E	48.02x
Benchmark P/E Range	3.87x to 667.16x
Company P/B Ratio	18.27x
Benchmark Median P/B	2.88x
Benchmark Average P/B	4.34x
Company ROE	18.31%
Benchmark Median ROE	11.81%
Benchmark Average ROE	11.21%
Company ROCE	18.2%
Benchmark Median ROCE	13.65%
Benchmark Average ROCE	13.76%
Company Market Capitalisation	Rs 1,04,566.62 crore
Benchmark Median Market Cap	Rs 683.05 crore
Benchmark Average Market Cap	Rs 14,252.9 crore

The industry benchmark reinforces that point. Across 201 same-industry companies, Laurus Labs’ P/E of 94.24 stands well above the median of 30.92 and the average of 48.02. The full range is wide at 3.87 to 667.16, but Laurus Labs still screens toward the richer end.

Price-to-book tells a similar story. The company’s P/B of 18.27 compares with a median of 2.88 and an average of 4.34 across 199 companies. Profitability looks better by comparison: ROE of 18.31% is above the industry median of 11.81% and average of 11.21%, while ROCE of 18.20% is above the median of 13.65% and average of 13.76%.

Scale also matters here. Laurus Labs, with a market cap of Rs 1,04,566.62 crore, is far larger than the industry median of Rs 683.05 crore and the average of Rs 14,252.90 crore. So the sector view is fairly clear: this is a much larger-than-typical pharma company with better-than-median profitability, yet it remains priced at a notable premium to benchmark valuation norms.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries	SUNPHARMA	4,60,696.31	38.8	5.43	14.85	19.11
Divi's Laboratories	DIVISLAB	2,46,062.83	83.91	13.89	16.19	21.51
Torrent Pharmaceuticals	TORNTPHARM	1,91,515.22	86.82	21.1	26.76	19.27
Zydus Lifesciences	ZYDUSLIFE	1,18,403.7	25.69	4.3	19.69	21.39
Cipla	CIPLA	1,14,554.33	33.94	3.25	11.83	16

Against major peers, Laurus Labs sits closer to Zydus Lifesciences and Cipla on market value than to the much larger Sun Pharmaceutical Industries or Divi's Laboratories. Its market cap of Rs 1,04,566.62 crore is below Sun Pharma, Divi's, Torrent, Zydus and Cipla as listed in the comparison set, though the gap with Zydus and Cipla is comparatively narrower than with the largest names.

On valuation, Laurus Labs is expensive relative to most of this peer group. Its P/E of 94.24 is above Sun Pharma at 38.80, Divi's at 83.91, Torrent at 86.82, Zydus at 25.69 and Cipla at 33.94. Its P/B of 18.27 is above Sun Pharma, Divi's, Zydus and Cipla, and below only Torrent Pharmaceuticals at 21.10.

Profitability is more mixed. ROE of 18.31% is above Sun Pharma, Divi's and Cipla, but below Torrent and Zydus. ROCE of 18.20% is above Cipla, close to Sun Pharma and Torrent, but below Divi's and Zydus. The peer takeaway is simple: Laurus Labs is not weak on returns, yet its valuation remains richer than most major comparables.

Why Investors Are Watching Laurus Labs

• The stock fell 2.86% to Rs 1,852.50 from the previous close of Rs 1,907.00.
• It opened at Rs 1,894.05, which was also the day’s high, and traded near the low of Rs 1,851.90.
• P/E of 94.24 and P/B of 18.27 are well above industry medians.
• ROE of 18.31% and ROCE of 18.20% remain above industry median and average levels.
• Its market cap of Rs 1,04,566.62 crore keeps the stock relevant within the large listed pharma universe.

Track Laurus Labs on Univest

Use Laurus Labs (LAURUSLABS) live share-price page, Univest top decliners screener and Univest market blogs to review live stock data, top decliners and related market analysis.

On Univest, Laurus Labs Share Price can be viewed alongside valuation ratios, peer comparison and broader sector context, helping readers connect daily market movement with longer-term financial metrics.

Frequently Asked Questions

Why is Laurus Labs Share Price falling today?

Ans.  The stock is down 2.86% at Rs 1,852.50 versus the previous close of Rs 1,907.00. The supplied data confirms the decline, but it does not establish a company-specific catalyst behind the move.

What is Laurus Labs Share Price Today?

Ans.  Laurus Labs Share Price Today is Rs 1,852.50. The stock opened at Rs 1,894.05, touched a high of Rs 1,894.05 and a low of Rs 1,851.90. The previous close was Rs 1,907.

What do Laurus Labs valuation ratios show?

Ans.  The company trades at a P/E of 94.24 and a P/B of 18.27. Both are above the same-industry median values of 30.92 and 2.88 respectively. The company trades at a P/E ratio of 94.24x.

How profitable is Laurus Labs compared with its industry?

Ans.  ROE is 18.31% and ROCE is 18.20%, both above the industry medians of 11.81% and 13.65%. The stock belongs to the Healthcare sector. Its industry classification is Pharmaceuticals & Drugs.

How does Laurus Labs compare with key pharma peers?

Ans.  Laurus Labs carries a higher P/E than Sun Pharma, Divi's, Torrent, Zydus and Cipla in the supplied comparison set, while its profitability metrics are competitive rather than uniformly strongest. Comparable listed companies include Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals.

Track Laurus Labs (LAURUSLABS) Share Price on Univest

Use Laurus Labs (LAURUSLABS) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.